Skip Ribbon Commands
Skip to main content

Trials open for cancer patients

Cancer patients are often invited to participate in trials and studies to improve treatments and cancer drugs. The table below lists all ongoing treatment and clinical drug trials open for cancer patients in our hospital.  

If you are interested in participating in any one of the trials, please contact the unit where you are being treated for further advice.

You can promote the scientific study of cancer and health if you consent to providing the hospital with blood or tissue samples taken as you are being treated for deposition in the hospital's biobank. You may obtain more information and download the consent form here.

 

CancerCODE OF TRIALSUMMARY
Gynecological cancers
Imagyn050A phase III, multicenter,randomized,study of atezolitzumab versus placebo administred in combination with paclitaxel,carboplatin and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube or primary peritoneal cancer
ENGOT-EN2-DGCGRandomized multicenter trial on the risk of recurrence for patients with cancer limited to the uterus. After surgery, adjuvant treatment or follow-up.
Pediatric cancers
NOPHO-DBH-AML2012 Phase III study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years
IntreALL 2010SR​International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010. A randomized Phase III Study Conducted by the

Resistant Disease Committee of the International BFM Study Group

SIOP PNET 5-MBAn international prospective study on clinically standard-risk meduloblastoma in children older than 3 to 5 years with low-risk biological profile (PNET 5 MB-LR) or average-risk biological profile
EURO-Ewing-2008A randomised trial for patients with localised or metastatic Ewing sarcomas
Einstein 14372Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism. EINSTEIN Junior Phase III: oral rivaroxaban in children with venous thrombosis
Einstein 17992An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
NOPHO ALL2008Treatment Protocol for Children (1.0 - 17.9 years of age) and young adults

(18-45 years of age) with Acute Lymphoblastic Leukemia.

Lymphomas 
Chronos-4A phase III,double-blind,controlled,multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL)
Bio-CHICBiomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Breast cancer
BOLDA randomized phase III study compairing trastuzumab,pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer
MonarchEOpen-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone receptorpositive, human epidermal receptor 2 negative, breast cancer
Urological cancers
IMVIGOR010Open, randomized, two-armed, phase III, multicenter study on atezolizumab vs. watchful waiting in the treatment of high-risk PD-L1-positive cancer of the urinary bladder with intramuscular invasion after cystectomy.
KEYNOTE-057Open clinical trial to assess the efficacy and safety of pembrolizumab (MK-3475) in the treatment of patients with cancer of the superficial layer of the urinary bladder and in whom treatment with BCG (Bacillus Calmette Guerin) is no longer efficacious or who do not tolerate such treatment
IMVIGOR130A phase III,multicenter,randomized,placebo-controlled study of atezolizumab (anti-PD-L1 antibody) as monotherapy and in combination with platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma
FINNBLADDER 9Treatment of stage Ta cancer of the urinary bladder with a high risk of relapse – blue-light cystoscopy and optimized dosage of mitomycin-C.
KEYNOTE-564A phase III, Randomized,double-blind,placebo-controlled clinical trial of pembrolizumab (MK3475) as monotherapy in adjuvant treatment of renal cell carcinoma post nephrectomy
HopeA randomized, double-blind, phase 2 trial to assess safety and efficacy of lenvatinib at two different starting doses in combination with everolimus in renal cell carsinoma following one prior VEGF-targeted treatment
SPCG-15Surgery or radiation therapy in the treatment of locally advanced prostate cancer – open, randomized clinical trial.
Head and neck cancers
POET-HNSProspective multiregister study on the incidence of perioperative cardiovascular events and hemorrhages in association with surgery for head and neck cancer.  Safety and effects of aspirin on perioperative bleeding.
E-NOSEInternational multicenter trial to study the use of the electronic nose in the diagnosis and treatment follow-up of head and neck cancers
Hematological cancer
M15-550Open-Label, Single-Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT-199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL) Including Those With the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment With a B-Cell Receptor Inhibitor
NMSG#24/15Phase 2 Study of Carfilzomib + Elotuzumab + Dexamethasone for Relapsed or Progressed Multiple Myeloma After 1-3 Prior Treatment Lines
NMSG#20/13Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT
Päivitetty: 07/06/2018 09:01